In Brief: Gynecare
This article was originally published in The Gray Sheet
Executive Summary
Gynecare: Submits premarket approval application to FDA for its ThermaChoice uterine balloon therapy system following completion of six-month follow-up from a 255-patient clinical trial of the device. The system is intended to treat menorrhagia, or excessive menstrual bleeding, a condition Gynecare says affects about 19% of menstruating women worldwide. Gynecare's clinical trial, conducted at 12 U.S. and two Canadian sites, compared use of ThermaChoice to electrosurgical ablation with a rollerball in women with blood flows of more than 80 cc each month. Based on a diary scoring system used in the study to assess blood loss, Gynecare says the two methods led to comparable reductions in blood loss. About 69.4% of ThermaChoice patients (n=131) were completed in less than 30 minutes versus 28.6% of rollerball patients (n=124)...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.